George Reed to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications George Reed has written about Tumor Necrosis Factor-alpha.
Connection Strength
1.454
-
Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-a antagonist therapies. Clin Exp Rheumatol. 2013 Mar-Apr; 31(2):189-94.
Score: 0.339
-
Hirako IC, Assis PA, Hojo-Souza NS, Reed G, Nakaya H, Golenbock DT, Coimbra RS, Gazzinelli RT. Daily Rhythms of TNFa Expression and Food Intake Regulate Synchrony of Plasmodium Stages with the Host Circadian Cycle. Cell Host Microbe. 2018 06 13; 23(6):796-808.e6.
Score: 0.124
-
Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015 Sep 18; 17:256.
Score: 0.103
-
Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015 Jul; 42(7):1090-8.
Score: 0.100
-
Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis. 2015 Jun; 74(6):1150-5.
Score: 0.097
-
Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015 Feb; 74(2):430-6.
Score: 0.091
-
Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken). 2011 Dec; 63(12):1672-9.
Score: 0.079
-
Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Apr; 70(4):576-82.
Score: 0.074
-
Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep; 69(9):1612-7.
Score: 0.071
-
Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010 Jan 15; 62(1):101-7.
Score: 0.069
-
Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, Kafka SP, Reed G, Kremer JM. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med. 2008 Jun; 121(6):532-8.
Score: 0.062
-
Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar; 77(3):263-271.
Score: 0.049
-
Bessette L, Movahedi M, Reed G, Kremer JM, Kane K, Keystone E. Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis? J Clin Rheumatol. 2023 Oct 01; 29(7):332-340.
Score: 0.044
-
Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 11; 74(11):1909-1916.
Score: 0.041
-
Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016 12 01; 18(1):280.
Score: 0.028
-
Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). 2015 Dec; 67(12):1671-8.
Score: 0.026
-
Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". BMC Musculoskelet Disord. 2014 Apr 01; 15:113.
Score: 0.023
-
Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
Score: 0.019
-
Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009 Jun; 15(4):155-60.
Score: 0.017